GAMMA Investing LLC Makes New Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

GAMMA Investing LLC bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 520 shares of the medical equipment provider’s stock, valued at approximately $65,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. PFG Advisors grew its position in shares of Zimmer Biomet by 4.6% in the 4th quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock worth $231,000 after buying an additional 84 shares during the period. Quent Capital LLC grew its position in shares of Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after buying an additional 92 shares during the period. Pinnacle Associates Ltd. grew its position in shares of Zimmer Biomet by 5.0% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider’s stock worth $227,000 after buying an additional 97 shares during the period. Financial Advocates Investment Management grew its position in shares of Zimmer Biomet by 3.8% in the 3rd quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider’s stock worth $295,000 after buying an additional 97 shares during the period. Finally, Stokes Family Office LLC grew its position in shares of Zimmer Biomet by 4.1% in the 3rd quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider’s stock worth $280,000 after buying an additional 99 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.70% of the company’s stock.

Analyst Ratings Changes

ZBH has been the topic of a number of recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 9th. Citigroup increased their price objective on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Thursday, February 8th. Canaccord Genuity Group reissued a “hold” rating and set a $130.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 23rd. Finally, StockNews.com downgraded shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $139.39.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $120.28 on Wednesday. The firm’s 50-day moving average price is $125.83 and its 200-day moving average price is $119.92. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. The company has a market cap of $24.71 billion, a PE ratio of 24.60, a PEG ratio of 2.23 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $149.25.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The firm had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. During the same quarter in the prior year, the business earned $1.88 EPS. The business’s quarterly revenue was up 6.3% on a year-over-year basis. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.08 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. The ex-dividend date was Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.